CTIS2023-506189-29-00进行中（未招募）1 期
A phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen, inactivated, adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19. - HIPRA-HH-11
Hipra Scientific S.L.0 个研究点目标入组 300 人开始时间: 2023年6月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 65 至 65+（—）
- 性别
- All
入选标准
- •Adults aged 65 or older at Day 0., Are willing and able to sign the informed consent and can comply with all study visits and procedures., Participant must have received at least a primary scheme of an mRNA vaccine (2 doses). Booster doses or previous COVID-19 infections are allowed. Last dose must have been administered at least 6 months before Day 0. History of COVID-19 infection is allowed if occurred at least >30 days before Day 0., Have a negative Rapid Antigen Test (RAT) at Day 0 before vaccinations., Adults determined by clinical assessment, including medical history and clinical judgement, to be eligible for the study, including adults with pre-existing chronic and stable diseases (non-immunocompromised), if these are stable and well-controlled according to the investigator’s judgment.
排除标准
- •Acute illness with fever = 38.0°C at Day 0 or within 24 hours prior to vaccination. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator., Participation in other studies involving study intervention within 28 days prior to screening and/or during study participation., Received any non-study vaccine within 14 days before or after screening. For live or attenuated vaccines, 4 weeks before or after screening., History of a diagnosis or other conditions that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety., Allergy to egg proteins (egg or egg products) or chicken proteins., History of Guillain-Barré syndrome (GBS), History of COVID-19 infection (described as a positive RAT or PCR), in the previous 30 days before Day 0., Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behaviour that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study., History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g. anaphylaxis) to any component of the study intervention(s)., Immunocompromised individuals defined as those with primary and secondary immune deficiencies and those receiving chemotherapy or immunosuppressant drugs other than steroids and glucocorticoids (maximum 30 mg/day of prednisone, or equivalent, by any administration route for a maximum of 30 consecutive days), within 90 days prior to vaccination or during the study., Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection., Receipt of blood-derived immune globulins, blood, or blood-derived products in the past 3 months.
研究者
相似试验
进行中（未招募）
不适用
A phase II, double-blind, randomized, multi-center, adaptive dose-ranging, placebo-controlled, parallel-group study evaluating safety, tolerability and efficacy on MRI lesion parameters and determining the dose response curve of BAF312 given orally once daily in patients with relapsingremitting multiple sclerosis - NDMedDRA version: 9.1Level: LLTClassification code 10028245Term: Multiple sclerosismultiple sclerosisEUCTR2008-008719-25-ITOVARTIS FARMA275
进行中（未招募）
不适用
A phase II, double-blind, randomized, multi-center, adaptive dose-ranging, placebo-controlled, parallel-group study evaluating safety, tolerability and efficacy on MRI lesion parameters and determining the dose response curve of BAF312 given orally once daily in patients with relapsing-remitting multiple sclerosisRelapsing-remitting multiple sclerosisMedDRA version: 9.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisEUCTR2008-008719-25-FIovartis Pharma Services AG275
进行中（未招募）
不适用
A phase II, double-blind, randomized, multi-center, adaptive dose-ranging, placebo-controlled, parallel-group study evaluating safety, tolerability and efficacy on MRI lesion parameters and determining the dose response curve of BAF312 given orally once daily in patients with relapsing-remitting multiple sclerosisRelapsing-remitting multiple sclerosisMedDRA version: 9.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisEUCTR2008-008719-25-DEovartis Pharma Services AG275
进行中（未招募）
不适用
A phase II, double-blind, randomized, multi-center, adaptive dose-ranging, placebo-controlled, parallel-group study evaluating safety, tolerability and efficacy on MRI lesion parameters and determining the dose response curve of BAF312 given orally once daily in patients with relapsing-remitting multiple sclerosisEUCTR2008-008719-25-HUovartis Pharma Services AG275
进行中（未招募）
不适用
Dose finding clinical study, multicentre, with allergy vaccines for patients allergic to Phleum pratense pollen at different doses and placebo, a substance with inactive ingredients of medicine and whose appearance is identical to that of the actual treatment in question.EUCTR2011-000814-21-PTBIAL INDUSTRIAL FARMACEUTICA, S.A.150